Stock 600223 LUSHANG FREDA PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Lushang Freda Pharmaceutical Co.,Ltd.

Equities

600223

CNE000001147

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
7.89 CNY -5.96% Intraday chart for Lushang Freda Pharmaceutical Co.,Ltd. -3.07% -18.07%
Apr. 29 Lushang Freda Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 21 Lushang Freda Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
LUSHANG FREDA PHARMACEUTICAL CO.,LTD. Stock Lushang Freda Pharmaceutical Co.,Ltd.
-18.07% 1.11B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.08% 662B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
B-
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
B+
NOVARTIS AG Stock Novartis AG
+3.65% 198B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
A+
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 600223 Stock
  4. Ratings Lushang Freda Pharmaceutical Co.,Ltd.